{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T10:17:57Z","timestamp":1771064277023,"version":"3.50.1"},"reference-count":211,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/148406\/2019"],"award-info":[{"award-number":["SFRH\/BD\/148406\/2019"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["contract IF\/01459\/2015"],"award-info":[{"award-number":["contract IF\/01459\/2015"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"funda\u00e7\u00e3o para a ci\u00eancia e a tecnologia","doi-asserted-by":"publisher","award":["2020.08310.BD"],"award-info":[{"award-number":["2020.08310.BD"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s00109-021-02106-x","type":"journal-article","created":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T08:02:59Z","timestamp":1625212979000},"page":"1349-1371","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Exploring the link between chronobiology and drug delivery: effects on cancer therapy"],"prefix":"10.1007","volume":"99","author":[{"given":"T\u00e2nia","family":"Albuquerque","sequence":"first","affiliation":[]},{"given":"Ana R.","family":"Neves","sequence":"additional","affiliation":[]},{"given":"Telma","family":"Quintela","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5049-4518","authenticated-orcid":false,"given":"Diana","family":"Costa","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,7,2]]},"reference":[{"key":"2106_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004882","volume":"4","author":"K Bozek","year":"2009","unstructured":"Bozek K, Rel\u00f3gio A, Kielbasa SM, Heine M, Dame C, Kramer A, Herzel H (2009) Regulation of clock-controlled genes in mammals. PLoS ONE 4:e4882. https:\/\/doi.org\/10.1371\/journal.pone.0004882","journal-title":"PLoS ONE"},{"key":"2106_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/b978-0-12-396971-2.00009-9","volume":"119","author":"L Fu","year":"2013","unstructured":"Fu L, Kettner NM (2013) The circadian clock in cancer development and therapy. Prog Mol Biol Transl Sci 119:221\u2013282. https:\/\/doi.org\/10.1016\/b978-0-12-396971-2.00009-9","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"3","key":"2106_CR3","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s11096-013-9749-0","volume":"35","author":"G Kaur","year":"2013","unstructured":"Kaur G, Phillips C, Wong K, Saini B (2013) Timing is important in medication administration: A timely review of chronotherapy research. Int J Clin Pharm 35(3):344\u2013358. https:\/\/doi.org\/10.1007\/s11096-013-9749-0","journal-title":"Int J Clin Pharm"},{"key":"2106_CR4","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1200\/jco.2006.06.1440","volume":"24","author":"S Giacchetti","year":"2006","unstructured":"Giacchetti S, Bjarnason G, Garufi C, Genet D, Iacobelli S, Tampellini M, Smaaland R, Focan C, Coudert B, Humblet Y et al (2006) Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil leucovorin and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol 24:3562\u20133569. https:\/\/doi.org\/10.1200\/jco.2006.06.1440","journal-title":"J Clin Oncol"},{"issue":"5","key":"2106_CR5","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/00498254.2019.1672120","volume":"50","author":"M Zhao","year":"2020","unstructured":"Zhao M, Xing H, Chen M, Dong D, Wu B (2020) Circadian clock-controlled drug metabolism and transport. Xenobiotica 50(5):495\u2013505. https:\/\/doi.org\/10.1080\/00498254.2019.1672120","journal-title":"Xenobiotica"},{"issue":"16","key":"2106_CR6","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1007\/s40265-016-0646-4","volume":"76","author":"JM Selfridge","year":"2016","unstructured":"Selfridge JM, Gotoh T, Schiffhauer S, Liu J, Stauffer PE, Li A, Capelluto DG, Finkielstein CV (2016) Chronotherapy: intuitive, sound, founded but not broadly applied. Drugs 76(16):1507\u20131521. https:\/\/doi.org\/10.1007\/s40265-016-0646-4","journal-title":"Drugs"},{"key":"2106_CR7","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s11096-013-9749-0","volume":"35","author":"G Kaur","year":"2013","unstructured":"Kaur G, Phillips C, Wong K, Saini B (2013) Timing is important in medication administration: a timely review of chronotherapy research. Int J Clin Pharm 35:344\u2013358. https:\/\/doi.org\/10.1007\/s11096-013-9749-0","journal-title":"Int J Clin Pharm"},{"key":"2106_CR8","unstructured":"Frick A (2016) A comprehensive gene regulatory network of the mammalian circadian clock a bioinformatic, statistics and network analysis approach to interrelate clock metrics and clock network metrics through the evaluation of readily available data sources. (Thesis Humboldt-Universit\u00e4t zu Berlin)."},{"key":"2106_CR9","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1146\/annurev.pharmtox.47.120505.105208","volume":"47","author":"F Levi","year":"2007","unstructured":"Levi F, Schibler U (2007) Circadian rhythms: mechanisms and therapeutic implications. Annu Rev Pharmacol Toxicol 47:593\u2013628. https:\/\/doi.org\/10.1146\/annurev.pharmtox.47.120505.105208","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2106_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5339\/jlghs.2013.3","volume":"1","author":"V Shanmugam","year":"2013","unstructured":"Shanmugam V, Wafi A, Al-Taweel N, B\u00fcsselberg D (2013) Disruption of circadian rhythm increases the risk of cancer metabolic syndrome and cardiovascular disease. J Local Glob Health Sci 1:3. https:\/\/doi.org\/10.5339\/jlghs.2013.3","journal-title":"J Local Glob Health Sci"},{"issue":"8","key":"2106_CR11","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3390\/cells8080883","volume":"8","author":"D Chowdhury","year":"2019","unstructured":"Chowdhury D, Wang C, Lu AP, Zhu HL (2019) Understanding quantitative circadian regulations are crucial towards advancing chronotherapy. Cells 8(8):883. https:\/\/doi.org\/10.3390\/cells8080883","journal-title":"Cells"},{"key":"2106_CR12","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/nrc2747","volume":"9","author":"S Sahar","year":"2009","unstructured":"Sahar S, Sassone-Corsi P (2009) Metabolism and cancer: the circadian clock connection. Nat Rev Cancer 9:886\u2013896. https:\/\/doi.org\/10.1038\/nrc2747","journal-title":"Nat Rev Cancer"},{"key":"2106_CR13","doi-asserted-by":"publisher","first-page":"682","DOI":"10.3389\/fphys.2019.00682","volume":"10","author":"Y Xie","year":"2019","unstructured":"Xie Y, Tang Q, Chen G, Xie M, Yu S, Zhao J, Chen L (2019) New insights into the circadian rhythm and its related diseases. Front Physiol 10:682. https:\/\/doi.org\/10.3389\/fphys.2019.00682","journal-title":"Front Physiol"},{"issue":"4","key":"2106_CR14","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3390\/clockssleep1040034","volume":"1","author":"MN Morgan","year":"2019","unstructured":"Morgan MN, Dvuchbabny S, Martinez CA, Kerr B, Cistulli PA, Cook KM (2019) The cancer clock is (not) ticking: links between circadian rhythms and cancer. Clocks and Sleep 1(4):435\u2013458. https:\/\/doi.org\/10.3390\/clockssleep1040034","journal-title":"Clocks and Sleep"},{"issue":"14","key":"2106_CR15","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.cub.2007.05.067","volume":"17","author":"JP DeBruyne","year":"2007","unstructured":"DeBruyne JP, Weaver DR, Reppert SM (2007) Peripheral circadian oscillators require CLOCK. Curr Biol 17(14):538\u2013539. https:\/\/doi.org\/10.1016\/j.cub.2007.05.067","journal-title":"Curr Biol"},{"issue":"5","key":"2106_CR16","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nn1884","volume":"10","author":"JP DeBruyne","year":"2007","unstructured":"DeBruyne JP, Weaver DR, Reppert SM (2007) CLOCK and NPAS2 have overlapping roles in the suprachiasmatic circadian clock. Nat Neurosci 10(5):543\u2013545. https:\/\/doi.org\/10.1038\/nn1884","journal-title":"Nat Neurosci"},{"issue":"5724","key":"2106_CR17","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1126\/science.1108750","volume":"308","author":"FW Turek","year":"2005","unstructured":"Turek FW, Joshu C, Kohsaka A, Lin E, Ivanova G, McDearmon E, Laposky A, Losee-Olson S, Easton A, Jensen DR et al (2005) Obesity and metabolic syndrome in circadian Clock mutant mice. Sci 308(5724):1043\u20131045. https:\/\/doi.org\/10.1126\/science.1108750","journal-title":"Sci"},{"issue":"3","key":"2106_CR18","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00429-014-0720-1","volume":"220","author":"T Quintela","year":"2015","unstructured":"Quintela T, Sousa C, Patriarca FM, Goncalves I, Santos CR (2015) Gender associated circadian oscillations of the clock genes in rat choroid plexus. Brain Struct Funct 220(3):1251\u20131262. https:\/\/doi.org\/10.1007\/s00429-014-0720-1","journal-title":"Brain Struct Funct"},{"issue":"5","key":"2106_CR19","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.cell.2013.01.055","volume":"152","author":"SH Yoo","year":"2013","unstructured":"Yoo SH, Mohawk JA, Siepka SM, Shan Y, Huh SK, Hong HK, Kornblum I, Kumar V, Koike N, Xu M et al (2013) Competing E3 ubiquitin ligases govern circadian periodicity by degradation of CRY in nucleus and cytoplasm. Cell 152(5):1091\u20131105. https:\/\/doi.org\/10.1016\/j.cell.2013.01.055","journal-title":"Cell"},{"issue":"2","key":"2106_CR20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41580-019-0179-2","volume":"21","author":"A Patke","year":"2020","unstructured":"Patke A, Young MW, Axelrod S (2020) Molecular mechanisms and physiological importance of circadian rhythms. Nat Rev Mol Cell Biol 21(2):67\u201384. https:\/\/doi.org\/10.1038\/s41580-019-0179-2","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"10","key":"2106_CR21","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.3390\/ijms18102168","volume":"18","author":"N Ozturk","year":"2017","unstructured":"Ozturk N, Ozturk D, Kavakli IH, Okyar A (2017) Molecular aspects of circadian pharmacology and relevance for cancer chronotherapy. Int J Mol Sci 18(10):2168. https:\/\/doi.org\/10.3390\/ijms18102168","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2106_CR22","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41416-019-0614-3","volume":"122","author":"M Fagny","year":"2020","unstructured":"Fagny M, Platig J, Kuijjer ML, Lin X, Quackenbush J (2020) Nongenic cancer-risk SNPs affect oncogenes tumour-suppressor genes and immune function. Br J Cancer 122(4):569\u2013577. https:\/\/doi.org\/10.1038\/s41416-019-0614-3","journal-title":"Br J Cancer"},{"issue":"6","key":"2106_CR23","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1159\/000495956","volume":"51","author":"LH Wang","year":"2018","unstructured":"Wang LH, Wu CF, Rajasekaran N, Shin YK (2018) Loss of tumor suppressor gene function in human cancer: an overview. Cellular Physiol Biochem 51(6):2647\u20132693. https:\/\/doi.org\/10.1159\/000495956","journal-title":"Cellular Physiol Biochem"},{"issue":"5","key":"2106_CR24","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.molmed.2016.03.004","volume":"22","author":"R Dallmann","year":"2016","unstructured":"Dallmann R, Okyar A, Levi F (2016) Dosing-time makes the poison: circadian regulation and pharmacotherapy. Trends Mol Med 22(5):430\u2013445. https:\/\/doi.org\/10.1016\/j.molmed.2016.03.004","journal-title":"Trends Mol Med"},{"key":"2106_CR25","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.2217\/fon-2017-0456","volume":"13","author":"S Kiessling","year":"2017","unstructured":"Kiessling S, Cermakian N (2017) The tumor circadian clock: a new target for cancer therapy? Future Oncol 13:2607\u20132610. https:\/\/doi.org\/10.2217\/fon-2017-0456","journal-title":"Future Oncol"},{"key":"2106_CR26","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.2147\/ott.s203144","volume":"12","author":"HX Li","year":"2019","unstructured":"Li HX (2019) The role of circadian clock genes in tumors. OncoTargets Ther 12:3645\u20133660. https:\/\/doi.org\/10.2147\/ott.s203144","journal-title":"OncoTargets Ther"},{"issue":"8","key":"2106_CR27","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.trecan.2019.07.002","volume":"5","author":"G Sulli","year":"2019","unstructured":"Sulli G, Lam MTY, Panda S (2019) Interplay between circadian clock and cancer: new frontiers for cancer treatment. Trends Cancer 5(8):475\u2013494. https:\/\/doi.org\/10.1016\/j.trecan.2019.07.002","journal-title":"Trends Cancer"},{"key":"2106_CR28","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3389\/fcell.2016.00062","volume":"4","author":"BJ Altman","year":"2016","unstructured":"Altman BJ (2016) Cancer clocks out for lunch: disruption of circadian rhythm and metabolic oscillation in cancer. Front Cell Dev Biol 4:62. https:\/\/doi.org\/10.3389\/fcell.2016.00062","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"2106_CR29","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1080\/07420520802384036","volume":"25","author":"B Coudert","year":"2008","unstructured":"Coudert B, Focan C, Genet D, Giacchetti S, Cvickovic F, Zambelli A, Fillet G, Chollet P, Amoroso D, Van Der Auwera J et al (2008) A randomized multicenter study of optimal circadian time of vinorelbine combined with chronomodulated 5-fluorouracil in pretreated metastatic breast cancer patients: EORTC trial 05971. Chronobiol Int 25(5):680\u2013696. https:\/\/doi.org\/10.1080\/07420520802384036","journal-title":"Chronobiol Int"},{"issue":"20","key":"2106_CR30","doi-asserted-by":"publisher","first-page":"3808","DOI":"10.1200\/JCO.2003.10.083","volume":"21","author":"HH Gallion","year":"2003","unstructured":"Gallion HH, Brunetto VL, Cibull M, Lentz SS, Reid G, Soper JT, Burger RA, Andersen W (2003) Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 21(20):3808\u20133813. https:\/\/doi.org\/10.1200\/JCO.2003.10.083","journal-title":"J Clin Oncol"},{"issue":"2","key":"2106_CR31","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s40675-017-0069-0","volume":"3","author":"MG Figueiro","year":"2017","unstructured":"Figueiro MG (2017) Disruption of circadian rhythms by light during day and night. Curr Sleep Med Rep 3(2):76\u201384. https:\/\/doi.org\/10.1007\/s40675-017-0069-0","journal-title":"Curr Sleep Med Rep"},{"key":"2106_CR32","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13073-019-0704-0","volume":"11","author":"F Rijo-Ferreira","year":"2019","unstructured":"Rijo-Ferreira F, Takahashi JS (2019) Genomics of circadian rhythms in health and disease. Genome Med 11:82. https:\/\/doi.org\/10.1186\/s13073-019-0704-0","journal-title":"Genome Med"},{"key":"2106_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000228","volume":"17","author":"Y Lee","year":"2019","unstructured":"Lee Y, Lahens NF, Zhang S, Bedont J, Field JM, Sehgal A (2019) G1\/S cell cycle regulators mediate effects of circadian dysregulation on tumor growth and provide targets for timed anticancer treatment. PLoS Biol 17:e3000228. https:\/\/doi.org\/10.1371\/journal.pbio.3000228","journal-title":"PLoS Biol"},{"key":"2106_CR34","doi-asserted-by":"publisher","first-page":"10982","DOI":"10.1038\/s41598-019-47480-2","volume":"9","author":"TT Pham","year":"2019","unstructured":"Pham TT, Lee ES, Kong SY, Kim J, Kim SY, Joo J, Yoon KA, Park B (2019) Night-shift work, circadian and melatonin pathway related genes and their interaction on breast cancer risk: evidence from a case-control study in Korean women. Sci Rep 9:10982. https:\/\/doi.org\/10.1038\/s41598-019-47480-2","journal-title":"Sci Rep"},{"issue":"22","key":"2106_CR35","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.2174\/092986712801661013","volume":"19","author":"M S\u00e1nchez-Hidalgo","year":"2012","unstructured":"S\u00e1nchez-Hidalgo M, Guerrero JM, Villegas I, Packham G, de la Lastra CA (2012) Melatonin a natural programmed cell death inducer in cancer. Curr Med Chem 19(22):3805\u20133821. https:\/\/doi.org\/10.2174\/092986712801661013","journal-title":"Curr Med Chem"},{"issue":"4","key":"2106_CR36","doi-asserted-by":"publisher","first-page":"432","DOI":"10.5271\/sjweh.3738","volume":"44","author":"M Pahwa","year":"2018","unstructured":"Pahwa M, Labr\u00e8che F, Demers PA (2018) Night shift work and breast cancer risk: what do the meta-analyses tell us? Scand J Work Environ Health 44(4):432\u2013435. https:\/\/doi.org\/10.5271\/sjweh.3738","journal-title":"Scand J Work Environ Health"},{"key":"2106_CR37","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.scitotenv.2017.07.056","volume":"607","author":"RM Lunn","year":"2017","unstructured":"Lunn RM, Blask DE, Coogan AN, Figueiro MG, Gorman MR, Hall JE, Hansen J, Nelson RJ, Panda S, Smolensky MH et al (2017) Health consequences of electric lighting practices in the modern world: a report on the National Toxicology Program\u2019s workshop on shift work at night artificial light at night and circadian disruption. Sci Total Environ 607:1073\u20131084. https:\/\/doi.org\/10.1016\/j.scitotenv.2017.07.056","journal-title":"Sci Total Environ"},{"key":"2106_CR38","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jsmc.2018.04.003","volume":"13","author":"L Kervezee","year":"2018","unstructured":"Kervezee L, Shechter A, Boivin DB (2018) Impact of shift work on the circadian timing system and health in women. Sleep Med Clin 13:295\u2013306. https:\/\/doi.org\/10.1016\/j.jsmc.2018.04.003","journal-title":"Sleep Med Clin"},{"key":"2106_CR39","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/839743","volume":"2011","author":"R Salgado-Delgado","year":"2011","unstructured":"Salgado-Delgado R, Tapia Osorio A, Saderi N, Escobar C (2011) Disruption of circadian rhythms: a crucial factor in the etiology of depression. Depress Res Treat 2011:839743. https:\/\/doi.org\/10.1155\/2011\/839743","journal-title":"Depress Res Treat"},{"key":"2106_CR40","doi-asserted-by":"publisher","unstructured":"Weissova K, Skrabalova J, Sk\u00e1lov\u00e1 K, Bendov\u00e1 Z, Koprivova J (2019) The effect of a common daily schedule on human circadian rhythms during the polar day in Svalbard: a field study. J Circadian Rhythms 17. https:\/\/doi.org\/10.5334\/jcr.186","DOI":"10.5334\/jcr.186"},{"key":"2106_CR41","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40101-016-0103-9","volume":"36","author":"M Adamsson","year":"2016","unstructured":"Adamsson M, Laike T, Morita T (2016) Annual variation in daily light exposure and circadian change of melatonin and cortisol concentrations at a northern latitude with large seasonal differences in photoperiod length. J Physiol Anthropol 36:6. https:\/\/doi.org\/10.1186\/s40101-016-0103-9","journal-title":"J Physiol Anthropol"},{"issue":"4","key":"2106_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-008127","volume":"5","author":"T Akerstedt","year":"2015","unstructured":"Akerstedt T, Knutsson A, Narusyte J, Svedberg P, Kecklund G, Alexanderson K (2015) Night work and breast cancer in women: a Swedish cohort study. BMJ Open 5(4):e008127. https:\/\/doi.org\/10.1136\/bmjopen-2015-008127","journal-title":"BMJ Open"},{"issue":"5","key":"2106_CR43","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1002\/ijc.29400","volume":"137","author":"K Papantoniou","year":"2015","unstructured":"Papantoniou K, Castano-Vinyals G, Espinosa A, Aragones N, Perez-Gomez B, Burgos J, Gomez-Acebo I, Llorca J, Peiro R, Jimenez-Moleon JJ et al (2015) Night shift work chronotype and prostate cancer risk in the MCC-Spain case-control study. Int J Cancer 137(5):1147\u20131157. https:\/\/doi.org\/10.1002\/ijc.29400","journal-title":"Int J Cancer"},{"issue":"28","key":"2106_CR44","doi-asserted-by":"publisher","first-page":"25046","DOI":"10.18632\/oncotarget.4502","volume":"6","author":"X Wang","year":"2015","unstructured":"Wang X, Ji A, Zhu Y, Liang Z, Wu J, Li S, Meng S, Zheng X, Xie L (2015) A meta-analysis including dose-response relationship between night shift work and the risk of colorectal cancer. Oncotarget 6(28):25046\u201325060. https:\/\/doi.org\/10.18632\/oncotarget.4502","journal-title":"Oncotarget"},{"issue":"9","key":"2106_CR45","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1093\/aje\/kws318","volume":"176","author":"ME Parent","year":"2012","unstructured":"Parent ME, El-Zein M, Rousseau MC, Pintos J, Siemiatycki J (2012) Night work and the risk of cancer among men. Am J Epidemiol 176(9):751\u2013759. https:\/\/doi.org\/10.1093\/aje\/kws318","journal-title":"Am J Epidemiol"},{"key":"2106_CR46","doi-asserted-by":"publisher","first-page":"7895","DOI":"10.2147\/ott.s174100","volume":"11","author":"Y Wang","year":"2018","unstructured":"Wang Y, Wang P, Zheng X, Du X (2018) Therapeutic strategies of melatonin in cancer patients: a systematic review and meta-analysis. OncoTargets Ther 11:7895\u20137908. https:\/\/doi.org\/10.2147\/ott.s174100","journal-title":"OncoTargets Ther"},{"issue":"3","key":"2106_CR47","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s11818-019-00215-x","volume":"23","author":"C Blume","year":"2019","unstructured":"Blume C, Garbazza C, Spitschan M (2019) Effects of light on human circadian rhythms, sleep and mood. Somnologie (Berl) 23(3):147\u2013156. https:\/\/doi.org\/10.1007\/s11818-019-00215-x","journal-title":"Somnologie (Berl)"},{"issue":"4","key":"2106_CR48","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1073\/pnas.1418490112","volume":"112","author":"AM Chang","year":"2015","unstructured":"Chang AM, Aeschbach D, Duffy JF, Czeisler CA (2015) Evening use of light-emitting eReaders negatively affects sleep circadian timing and next-morning alertness. Proc Natl Acad Sci USA 112(4):1232\u20131237. https:\/\/doi.org\/10.1073\/pnas.1418490112","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1667","key":"2106_CR49","doi-asserted-by":"publisher","first-page":"20140121","DOI":"10.1098\/rstb.2014.0121","volume":"370","author":"A Haim","year":"2015","unstructured":"Haim A, Zubidat AE (2015) Artificial light at night: melatonin as a mediator between the environment and epigenome. Philos Trans R Soc Lond B Biol Sci 370(1667):20140121. https:\/\/doi.org\/10.1098\/rstb.2014.0121","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"15","key":"2106_CR50","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1158\/0008-5472.CAN-13-3156","volume":"74","author":"RT Dauchy","year":"2014","unstructured":"Dauchy RT, Xiang S, Mao L, Brimer S, Wren MA, Yuan L, Anbalagan M, Hauch A, Frasch T, Rowan BG et al (2014) Circadian and melatonin disruption by exposure to light at night drives intrinsic resistance to tamoxifen therapy in breast cancer. Cancer Res 74(15):4099\u20134110. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-3156","journal-title":"Cancer Res"},{"key":"2106_CR51","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1002\/ijc.31649","volume":"143","author":"M Kogevinas","year":"2018","unstructured":"Kogevinas M, Espinosa A, Castell\u00f3 A, G\u00f3mez-Acebo I, Guevara M, Martin V, Amiano P, Alguacil J, Peiro R, Moreno V et al (2018) Effect of mistimed eating patterns on breast and prostate cancer risk (MCC-Spain Study). Int J Cancer 143:2380\u20132389. https:\/\/doi.org\/10.1002\/ijc.31649","journal-title":"Int J Cancer"},{"key":"2106_CR52","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1002\/ijc.31584","volume":"143","author":"B Srour","year":"2018","unstructured":"Srour B, Plancoulaine S, Andreeva VA, Fassier P, Julia C, Galan P, Hercberg S, Deschasaux M, Latino-Martel P, Touvier M (2018) Circadian nutritional behaviours and cancer risk: new insights from the NutriNet-sante prospective cohort study: Disclaimers. Int J Cancer 143:2369\u20132379. https:\/\/doi.org\/10.1002\/ijc.31584","journal-title":"Int J Cancer"},{"key":"2106_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.sleep.2019.07.023","volume":"66","author":"RM Kelly","year":"2020","unstructured":"Kelly RM, Finn J, Healy U, Gallen D, Sreenan S, McDermott JH, Coogan AN (2020) Greater social jetlag associates with higher HbA1c in adults with type 2 diabetes: a cross sectional study. Sleep Med 66:1\u20139. https:\/\/doi.org\/10.1016\/j.sleep.2019.07.023","journal-title":"Sleep Med"},{"issue":"4","key":"2106_CR54","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1177\/0748730417713572","volume":"32","author":"ADM Koopman","year":"2017","unstructured":"Koopman ADM, Rauh SP, van \u2019t Riet E, Groeneveld L, van der Heijden AA, Elders PJ, Dekker JM, Nijpels G, Beulens JW, Rutters F, (2017) The association between social jetlag the metabolic syndrome and type 2 diabetes mellitus in the general population: the New Hoorn Study. J Biol Rhythms 32(4):359\u2013368. https:\/\/doi.org\/10.1177\/0748730417713572","journal-title":"J Biol Rhythms"},{"issue":"6","key":"2106_CR55","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.ccell.2016.10.007","volume":"30","author":"NM Kettner","year":"2016","unstructured":"Kettner NM, Voicu H, Finegold MJ, Coarfa C, Sreekumar A, Putluri N, Katchy CA, Lee C, Moore DD, Fu L (2016) Circadian homeostasis of liver metabolism suppresses hepatocarcinogenesis. Cancer Cell 30(6):909\u2013924. https:\/\/doi.org\/10.1016\/j.ccell.2016.10.007","journal-title":"Cancer Cell"},{"issue":"9","key":"2106_CR56","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1289\/ehp.10200","volume":"115","author":"RG Stevens","year":"2007","unstructured":"Stevens RG, Blask DE, Brainard GC, Hansen J, Lockley SW, Provencio I, Rea MS, Reinlib L (2007) Meeting report: the role of environmental lighting and circadian disruption in cancer and other diseases. Environ Health Perspect 115(9):1357\u20131362. https:\/\/doi.org\/10.1289\/ehp.10200","journal-title":"Environ Health Perspect"},{"key":"2106_CR57","doi-asserted-by":"publisher","first-page":"4845059","DOI":"10.1155\/2017\/4845059","volume":"2017","author":"C Lu","year":"2017","unstructured":"Lu C, Sun H, Huang J, Yin S, Hou W, Zhang J, Wang Y, Xu Y, Xu H (2017) Long-term sleep duration as a risk factor for breast cancer: evidence from a systematic review and dose-response meta-analysis. BioMed Res Int 2017:4845059. https:\/\/doi.org\/10.1155\/2017\/4845059","journal-title":"BioMed Res Int"},{"issue":"4","key":"2106_CR58","doi-asserted-by":"publisher","first-page":"495","DOI":"10.5664\/jcsm.5674","volume":"12","author":"AI Phipps","year":"2016","unstructured":"Phipps AI, Bhatti P, Neuhouser ML, Chen C, Crane TE, Kroenke CH, Ochs-Balcom H, Rissling M, Snively BM, Stefanick ML et al (2016) Pre-diagnostic sleep duration and sleep quality in relation to subsequent cancer survival. J Clin Sleep Med 12(4):495\u2013503. https:\/\/doi.org\/10.5664\/jcsm.5674","journal-title":"J Clin Sleep Med"},{"issue":"12","key":"2106_CR59","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.5665\/sleep.4244","volume":"37","author":"CA Everson","year":"2014","unstructured":"Everson CA, Henchen CJ, Szabo A, Hogg N (2014) Cell injury and repair resulting from sleep loss and sleep recovery in laboratory rats. Sleep 37(12):1929\u20131940. https:\/\/doi.org\/10.5665\/sleep.4244","journal-title":"Sleep"},{"issue":"1","key":"2106_CR60","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1749-6632.2009.05300.x","volume":"1193","author":"T Lange","year":"2010","unstructured":"Lange T, Dimitrov S, Born J (2010) Effects of sleep and circadian rhythm on the human immune system. Ann N Y Acad Sci 1193(1):48\u201359. https:\/\/doi.org\/10.1111\/j.1749-6632.2009.05300.x","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"2106_CR61","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.molcel.2006.03.038","volume":"22","author":"S Gery","year":"2006","unstructured":"Gery S, Komatsu N, Baldjyan L, Yu A, Koo D, Koeffler HP (2006) The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell 22(3):375\u2013382. https:\/\/doi.org\/10.1016\/j.molcel.2006.03.038","journal-title":"Mol Cell"},{"key":"2106_CR62","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/s0092-8674(02)00961-3","volume":"111","author":"L Fu","year":"2002","unstructured":"Fu L, Pelicano H, Liu J, Huang P, Lee C (2002) The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 111:41\u201350. https:\/\/doi.org\/10.1016\/s0092-8674(02)00961-3","journal-title":"Cell"},{"key":"2106_CR63","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1182\/blood-2005-01-0358","volume":"106","author":"S Gery","year":"2005","unstructured":"Gery S, Gombart AF, Yi WS, Koeffler C, Hofmann WK, Koeffler HP (2005) Transcription profiling of C\/EBP targets identifies Per2 as a gene implicated in myeloid leukemia. Blood 106:2827\u20132836. https:\/\/doi.org\/10.1182\/blood-2005-01-0358","journal-title":"Blood"},{"issue":"1","key":"2106_CR64","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1158\/1055-9965.268.14.1","volume":"14","author":"Y Zhu","year":"2005","unstructured":"Zhu Y, Brown HN, Zhang Y, Stevens RG, Zheng T (2005) Period3 structural variation: a circadian biomarker associated with breast cancer in young women. Cancer Epidemiol Biomark Prev 14(1):268\u2013270","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"3","key":"2106_CR65","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s10549-007-9565-0","volume":"107","author":"Y Zhu","year":"2008","unstructured":"Zhu Y, Stevens RG, Leaderer D, Hoffman A, Holford T, Zhang Y, Brown HN, Zheng T (2008) Non-synonymous polymorphisms in the circadian gene NPAS2 and breast cancer risk. Breast Cancer Res Treatment 107(3):421\u2013425. https:\/\/doi.org\/10.1007\/s10549-007-9565-0","journal-title":"Breast Cancer Res Treatment"},{"issue":"7","key":"2106_CR66","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1093\/carcin\/bgi075","volume":"26","author":"ST Chen","year":"2005","unstructured":"Chen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ, Chang JG (2005) Deregulated expression of the PER1 PER2 and PER3 genes in breast cancers. Carcinogenesis 26(7):1241\u20131246. https:\/\/doi.org\/10.1093\/carcin\/bgi075","journal-title":"Carcinogenesis"},{"issue":"5","key":"2106_CR67","doi-asserted-by":"publisher","first-page":"4816","DOI":"10.3892\/ol.2019.10830","volume":"18","author":"W Yuan","year":"2019","unstructured":"Yuan W, Liu L, Wei C, Li X, Sun D, Dai C, Li S, Peng S, Jiang L (2019) Identification and meta-analysis of copy number variation-driven circadian clock genes for colorectal cancer. Oncol Lett 18(5):4816\u20134824. https:\/\/doi.org\/10.3892\/ol.2019.10830","journal-title":"Oncol Lett"},{"key":"2106_CR68","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/978-1-4939-8751-1_10","volume":"1856","author":"E Reszka","year":"2018","unstructured":"Reszka E, Zienolddiny S (2018) Epigenetic basis of circadian rhythm disruption in cancer. Methods Mol Biol 1856:173\u2013201. https:\/\/doi.org\/10.1007\/978-1-4939-8751-1_10","journal-title":"Methods Mol Biol"},{"key":"2106_CR69","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/CCO.0000000000000153","volume":"27","author":"S Masri","year":"2015","unstructured":"Masri S, Kinouchi K, Sassone-Corsi P (2015) Circadian clocks epigenetics and cancer. Curr Opin Oncol 27:50\u201356. https:\/\/doi.org\/10.1097\/CCO.0000000000000153","journal-title":"Curr Opin Oncol"},{"issue":"3","key":"2106_CR70","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.cels.2018.01.013","volume":"6","author":"Y Ye","year":"2018","unstructured":"Ye Y, Xiang Y, Ozguc FM, Kim Y, Liu CJ, Park PK, Hu Q, Diao L, Lou Y, Lin C et al (2018) The genomic landscape and pharmacogenomic interactions of clock genes in cancer chronotherapy. Cell Syst 6(3):314\u2013328. https:\/\/doi.org\/10.1016\/j.cels.2018.01.013","journal-title":"Cell Syst"},{"issue":"11","key":"2106_CR71","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1002\/ijc.31655","volume":"143","author":"K Papantoniou","year":"2018","unstructured":"Papantoniou K, Devore EE, Massa J, Strohmaier S, Vetter C, Yang L, Shi Y, Giovannucci E, Speizer F, Schernhammer ES (2018) Rotating night shift work and colorectal cancer risk in the nurses\u2019 health studies. Int J Cancer 143(11):2709\u20132717. https:\/\/doi.org\/10.1002\/ijc.31655","journal-title":"Int J Cancer"},{"issue":"5","key":"2106_CR72","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1093\/aje\/kwx140","volume":"186","author":"LR Wegrzyn","year":"2017","unstructured":"Wegrzyn LR, Tamimi RM, Rosner BA, Brown SB, Stevens RG, Eliassen AH, Laden F, Willett WC, Hankinson SE, Schernhammer ES (2017) Rotating night-shift work and the risk of breast cancer in the nurses\u2019 health studies. Am J Epidemiol 186(5):532\u2013540. https:\/\/doi.org\/10.1093\/aje\/kwx140","journal-title":"Am J Epidemiol"},{"key":"2106_CR73","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s10654-018-0368-x","volume":"33","author":"E Cordina-Duverger","year":"2018","unstructured":"Cordina-Duverger E, Menegaux F, Popa A, Rabstein S, Harth V, Pesch B, Bruning T, Fritschi L, Glass DC, Heyworth JS et al (2018) Night shift work and breast cancer: a pooled analysis of population-based case-control studies with complete work history. Eur J Epidemiol 33:369\u2013379. https:\/\/doi.org\/10.1007\/s10654-018-0368-x","journal-title":"Eur J Epidemiol"},{"issue":"14","key":"2106_CR74","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/j.cub.2015.06.012","volume":"25","author":"KC Van Dycke","year":"2015","unstructured":"Van Dycke KC, Rodenburg W, van Oostrom CT, van Kerkhof LW, Pennings JL, Roenneberg T, van Steeg H, van der Horst GT (2015) Chronically alternating light cycles increase breast cancer risk in mice. Curr Biol 25(14):1932\u20131937. https:\/\/doi.org\/10.1016\/j.cub.2015.06.012","journal-title":"Curr Biol"},{"issue":"5","key":"2106_CR75","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3109\/07420528.2015.1032413","volume":"32","author":"YJ Kim","year":"2015","unstructured":"Kim YJ, Lee E, Lee HS, Kim M, Park MS (2015) High prevalence of breast cancer in light polluted areas in urban and rural regions of South Korea: an ecologic study on the treatment prevalence of female cancers based on National Health Insurance data. Chronobiol Int 32(5):657\u2013667. https:\/\/doi.org\/10.3109\/07420528.2015.1032413","journal-title":"Chronobiol Int"},{"key":"2106_CR76","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.scitotenv.2018.02.101","volume":"628","author":"ZA Khan","year":"2018","unstructured":"Khan ZA, Labala RK, Yumnamcha T, Devi SD, Mondal G, Sanjita Devi H, Rajiv C, Bharali R, Chattoraj A (2018) Artificial Light at Night (ALAN) an alarm to ovarian physiology: a study of possible chronodisruption on zebrafish (Danio rerio). Sci Total Environ 628:1407\u20131421. https:\/\/doi.org\/10.1016\/j.scitotenv.2018.02.101","journal-title":"Sci Total Environ"},{"issue":"2","key":"2106_CR77","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jcmgh.2019.10.011","volume":"9","author":"F Bishehsari","year":"2020","unstructured":"Bishehsari F, Engen PA, Voigt RM, Swanson G, Shaikh M, Wilber S, Naqib A, Green SJ, Shetuni B, Forsyth CB et al (2020) Abnormal eating patterns cause circadian disruption and promote alcohol-associated colon carcinogenesis. Cell Mol Gastroenterol Hepatol 9(2):219\u2013237. https:\/\/doi.org\/10.1016\/j.jcmgh.2019.10.011","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"5","key":"2106_CR78","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1158\/1055-9965.epi-14-1292","volume":"24","author":"CR Marinac","year":"2015","unstructured":"Marinac CR, Natarajan L, Sears DD, Gallo LC, Hartman SJ, Arredondo E, Patterson RE (2015) Prolonged nightly fasting and breast cancer risk: findings from NHANES (2009\u20132010). Cancer Epidemiol Biomark Prev 24(5):783\u2013789. https:\/\/doi.org\/10.1158\/1055-9965.epi-14-1292","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"2106_CR79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010995","volume":"5","author":"S Lee","year":"2010","unstructured":"Lee S, Donehower LA, Herron AJ, Moore DD, Fu L (2010) Disrupting circadian homeostasis of sympathetic signaling promotes tumor development in mice. PLoS ONE 5:e10995. https:\/\/doi.org\/10.1371\/journal.pone.0010995","journal-title":"PLoS ONE"},{"key":"2106_CR80","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/978-1-4615-4253-7_17","volume":"4","author":"GA Bjarnason","year":"2000","unstructured":"Bjarnason GA, Jordan R (2000) Circadian variation of cell proliferation and cell cycle protein expression in man: clinical implications. Prog Cell Cycle Res 4:193\u2013206. https:\/\/doi.org\/10.1007\/978-1-4615-4253-7_17","journal-title":"Prog Cell Cycle Res"},{"issue":"2","key":"2106_CR81","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/s0002-9440(10)65306-0","volume":"154","author":"GA Bjarnason","year":"1999","unstructured":"Bjarnason GA, Jordan RC, Sothern RB (1999) Circadian variation in the expression of cell-cycle proteins in human oral epithelium. Am J Pathol 154(2):613\u2013622. https:\/\/doi.org\/10.1016\/s0002-9440(10)65306-0","journal-title":"Am J Pathol"},{"issue":"5","key":"2106_CR82","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1016\/s0002-9440(10)64135-1","volume":"158","author":"GA Bjarnason","year":"2001","unstructured":"Bjarnason GA, Jordan RC, Wood PA, Li Q, Lincoln DW, Sothern RB, Hrushesky WJ, Ben-David Y (2001) Circadian expression of clock genes in human oral mucosa and skin: association with specific cell-cycle phases. Am J Pathol 158(5):1793\u20131801. https:\/\/doi.org\/10.1016\/s0002-9440(10)64135-1","journal-title":"Am J Pathol"},{"key":"2106_CR83","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1126\/science.1086271","volume":"302","author":"T Matsuo","year":"2003","unstructured":"Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, Okamura H (2003) Control mechanism of the circadian clock for timing of cell division in vivo. Sci 302:255\u2013259. https:\/\/doi.org\/10.1126\/science.1086271","journal-title":"Sci"},{"key":"2106_CR84","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.2147\/ott.s100952","volume":"9","author":"XJ Fu","year":"2016","unstructured":"Fu XJ, Li HX, Yang K, Chen D, Tang H (2016) The important tumor suppressor role of PER1 in regulating the cyclin-CDK-CKI network in SCC15 human oral squamous cell carcinoma cells. Onco Targets Ther 9:2237\u20132245. https:\/\/doi.org\/10.2147\/ott.s100952","journal-title":"Onco Targets Ther"},{"key":"2106_CR85","doi-asserted-by":"publisher","first-page":"20574","DOI":"10.18632\/oncotarget.7827","volume":"7","author":"HX Li","year":"2016","unstructured":"Li HX, Fu XJ, Yang K, Chen D, Tang H, Zhao Q (2016) The clock gene PER1 suppresses expression of tumor-related genes in human oral squamous cell carcinoma. Oncotarget 7:20574\u201320583. https:\/\/doi.org\/10.18632\/oncotarget.7827","journal-title":"Oncotarget"},{"key":"2106_CR86","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/j.1349-7006.2006.00225.x","volume":"97","author":"H Hua","year":"2006","unstructured":"Hua H, Wang Y, Wan C, Liu Y, Zhu B, Yang C, Wang X, Wang Z, Cornelissen-Guillaume G, Halberg F (2006) Circadian gene mPer2 overexpression induces cancer cell apoptosis. Cancer Sci 97:589\u2013596. https:\/\/doi.org\/10.1111\/j.1349-7006.2006.00225.x","journal-title":"Cancer Sci"},{"issue":"3","key":"2106_CR87","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s12253-009-9227-0","volume":"16","author":"CM Sun","year":"2010","unstructured":"Sun CM, Huang SF, Zeng JM, Liu DB, Xiao Q, Tian WJ, Zhu XD, Huang ZG, Feng WL (2010) Per2 inhibits k562 leukemia cell growth in vitro and in vivo through cell cycle arrest and apoptosis induction. Pathol Oncol Res 16(3):403\u2013411. https:\/\/doi.org\/10.1007\/s12253-009-9227-0","journal-title":"Pathol Oncol Res"},{"issue":"19","key":"2106_CR88","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1091\/mbc.E14-05-0993","volume":"25","author":"T Gotoh","year":"2014","unstructured":"Gotoh T, Vila-Caballer M, Santos CS, Liu J, Yang J, Finkielstein CV (2014) The circadian factor Period 2 modulates p53 stability and transcriptional activity in unstressed cells. Mol Biol Cell 25(19):3081\u20133093. https:\/\/doi.org\/10.1091\/mbc.E14-05-0993","journal-title":"Mol Biol Cell"},{"key":"2106_CR89","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1091\/mbc.E14-05-0994","volume":"26","author":"T Gotoh","year":"2015","unstructured":"Gotoh T, Vila-Caballer M, Liu J, Schiffhauer S, Finkielstein CV (2015) Association of the circadian factor Period 2 to p53 influences p53\u2019s function in DNA-damage signaling. Mol Biol Cell 26:359\u2013372. https:\/\/doi.org\/10.1091\/mbc.E14-05-0994","journal-title":"Mol Biol Cell"},{"key":"2106_CR90","doi-asserted-by":"publisher","first-page":"27350","DOI":"10.18632\/oncotarget.8439","volume":"7","author":"N Zhanfeng","year":"2016","unstructured":"Zhanfeng N, Chengquan W, Hechun X, Jun W, Lijian Z, Dede M, Wenbin L, Lei Y (2016) Period2 downregulation inhibits glioma cell apoptosis by activating the MDM2-TP53 pathway. Oncotarget 7:27350\u201327362. https:\/\/doi.org\/10.18632\/oncotarget.8439","journal-title":"Oncotarget"},{"key":"2106_CR91","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004798","volume":"4","author":"J Mullenders","year":"2009","unstructured":"Mullenders J, Fabius AWM, Madiredjo M, Bernards R, Beijersbergen RL (2009) A large scale shRNA barcode screen identifies the circadian clock component ARNTL as putative regulator of the p53 tumor suppressor pathway. PLoS ONE 4:e4798. https:\/\/doi.org\/10.1371\/journal.pone.0004798","journal-title":"PLoS ONE"},{"issue":"12","key":"2106_CR92","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.3390\/molecules22122045","volume":"22","author":"M Schmidt","year":"2017","unstructured":"Schmidt M, Rohe A, Platzer C, Najjar A, Erdmann F, Sippl W (2017) Regulation of G2\/M transition by inhibition of WEE1 and PKMYT1 kinases. Molecules 22(12):2045. https:\/\/doi.org\/10.3390\/molecules22122045","journal-title":"Molecules"},{"key":"2106_CR93","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.4327","volume":"6","author":"J Shilts","year":"2018","unstructured":"Shilts J, Chen G, Hughey JJ (2018) Evidence for widespread dysregulation of circadian clock progression in human cancer. PeerJ 6:e4327. https:\/\/doi.org\/10.7717\/peerj.4327","journal-title":"PeerJ"},{"issue":"5","key":"2106_CR94","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.3892\/or.2018.6704","volume":"40","author":"R Xiang","year":"2018","unstructured":"Xiang R, Cui Y, Wang Y, Xie T, Yang X, Wang Z, Li J, Li Q (2018) Circadian clock gene Per2 downregulation in nonsmall cell lung cancer is associated with tumour progression and metastasis. Oncol Rep 40(5):3040\u20133048. https:\/\/doi.org\/10.3892\/or.2018.6704","journal-title":"Oncol Rep"},{"key":"2106_CR95","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.canlet.2015.12.002","volume":"371","author":"W Jiang","year":"2016","unstructured":"Jiang W, Zhao S, Jiang X, Zhang E, Hu G, Hu B, Zheng P, Xiao J, Lu Z, Lu Y et al (2016) The circadian clock gene Bmal1 acts as a potential anti-oncogene in pancreatic cancer by activating the p53 tumor suppressor pathway. Cancer Lett 371:314\u2013325. https:\/\/doi.org\/10.1016\/j.canlet.2015.12.002","journal-title":"Cancer Lett"},{"key":"2106_CR96","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199622","volume":"13","author":"M Lesicka","year":"2018","unstructured":"Lesicka M, Jab\u0142o\u0144ska E, Wieczorek E, Seroczy\u0144ska B, Siekierzycka A, Skokowski J, Kalinowski L, W\u0105sowicz W, Reszka E (2018) Altered circadian genes expression in breast cancer tissue according to the clinical characteristics. PLoS ONE 13:e0199622. https:\/\/doi.org\/10.1371\/journal.pone.0199622","journal-title":"PLoS ONE"},{"key":"2106_CR97","doi-asserted-by":"publisher","first-page":"34128","DOI":"10.18632\/oncotarget.16699","volume":"8","author":"H Hojo","year":"2017","unstructured":"Hojo H, Enya S, Arai M, Suzuki Y, Nojiri T, Kangawa K, Koyama S, Kawaoka S (2017) Remote reprogramming of hepatic circadian transcriptome by breast cancer. Oncotarget 8:34128\u201334140. https:\/\/doi.org\/10.18632\/oncotarget.16699","journal-title":"Oncotarget"},{"key":"2106_CR98","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/cncr.11040","volume":"97","author":"MC Mormont","year":"2003","unstructured":"Mormont MC, Levi F (2003) Cancer chronotherapy: principles applications and perspectives. Cancer 97:155\u2013169. https:\/\/doi.org\/10.1002\/cncr.11040","journal-title":"Cancer"},{"key":"2106_CR99","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.addr.2010.01.006","volume":"62","author":"S Ohdo","year":"2010","unstructured":"Ohdo S (2010) Chronotherapeutic strategy: rhythm monitoring manipulation and disruption. Adv Drug Deliv Rev 62:859\u2013875. https:\/\/doi.org\/10.1016\/j.addr.2010.01.006","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"2106_CR100","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1248\/bpb.33.159","volume":"33","author":"S Ohdo","year":"2010","unstructured":"Ohdo S (2010) Chronopharmaceutics: pharmaceutics focused on biological rhythm. Biol Pharm Bull 33(2):159\u2013167. https:\/\/doi.org\/10.1248\/bpb.33.159","journal-title":"Biol Pharm Bull"},{"issue":"6","key":"2106_CR101","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.3109\/07420520903237984","volume":"26","author":"B Lemmer","year":"2009","unstructured":"Lemmer B (2009) Discoveries of rhythms in human biological functions: a historical review. Chronobiol Int 26(6):1019\u20131068. https:\/\/doi.org\/10.3109\/07420520903237984","journal-title":"Chronobiol Int"},{"issue":"6","key":"2106_CR102","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/nan.0000000000000140","volume":"38","author":"P Librodo","year":"2015","unstructured":"Librodo P, Buckley M, Luk M, Bisso A (2015) Chronotherapeutic Drug Delivery. J Infus Nurs 38(6):18\u201323. https:\/\/doi.org\/10.1097\/nan.0000000000000140","journal-title":"J Infus Nurs"},{"key":"2106_CR103","doi-asserted-by":"publisher","first-page":"e14035","DOI":"10.1200\/JCO.2018.36.15_suppl.e14035","volume":"36","author":"JL Campian","year":"2018","unstructured":"Campian JL, Talcott G, Meyer M, Slat E, Avvaru C, Bhatta P, Rubin J (2018) Randomized feasibility study of temozolomide chronotherapy for high grade glioma. J Clin Oncol 36:e14035\u2013e14035. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.e14035","journal-title":"J Clin Oncol"},{"key":"2106_CR104","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1080\/07420528.2017.1397684","volume":"35","author":"PX Zhang","year":"2018","unstructured":"Zhang PX, Jin F, Li ZL, Wu WL, Li YY, Long JH, Chen GY, Chen XX, Gan JY, Gong XY et al (2018) A randomized phase II trial of induction chemotherapy followed by cisplatin chronotherapy versus constant rate delivery combined with radiotherapy. Chronobiol Int 35:240\u2013248. https:\/\/doi.org\/10.1080\/07420528.2017.1397684","journal-title":"Chronobiol Int"},{"key":"2106_CR105","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.3390\/molecules13081551","volume":"13","author":"N Zhang","year":"2008","unstructured":"Zhang N, Yin Y, Xu SJ, Chen WS (2008) 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules 13:1551\u20131569. https:\/\/doi.org\/10.3390\/molecules13081551","journal-title":"Molecules"},{"key":"2106_CR106","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/s0140-6736(97)03358-8","volume":"350","author":"F L\u00e9vi","year":"1997","unstructured":"L\u00e9vi F, Zidani R, Misset JL (1997) Randomised multicentre trial of chronotherapy with oxaliplatin fluorouracil and folinic acid in metastatic colorectal cancer. Lancet 350:681\u2013686. https:\/\/doi.org\/10.1016\/s0140-6736(97)03358-8","journal-title":"Lancet"},{"key":"2106_CR107","doi-asserted-by":"publisher","first-page":"4148","DOI":"10.1002\/cam4.3056","volume":"9","author":"PF Innominato","year":"2020","unstructured":"Innominato PF, Ballesta A, Huang Q, Focan C, Chollet P, Karabou\u00e9 A, Giacchetti S, Bouchahda M, Adam R, Garufi C et al (2020) Sex-dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial. Cancer Med 9:4148\u20134159. https:\/\/doi.org\/10.1002\/cam4.3056","journal-title":"Cancer Med"},{"key":"2106_CR108","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/0748730417696788","volume":"32","author":"EA Slat","year":"2017","unstructured":"Slat EA, Sponagel J, Marpegan L, Simon T, Kfoury N, Kim A, Binz A, Herzog ED, Rubin JB (2017) Cell-intrinsic Bmal1-dependent circadian regulation of temozolomide sensitivity in glioblastoma. J Biol Rhythms 32:121\u2013129. https:\/\/doi.org\/10.1177\/0748730417696788","journal-title":"J Biol Rhythms"},{"issue":"12","key":"2106_CR109","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1093\/annonc\/mds148","volume":"23","author":"S Giacchetti","year":"2012","unstructured":"Giacchetti S, Dugu\u00e9 PA, Innominato PF, Bjarnason GA, Focan C, Garufi C, Tumolo S, Coudert B, Iacobelli S, Smaaland R et al (2012) Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis. Ann Oncol 23(12):3110\u20133116. https:\/\/doi.org\/10.1093\/annonc\/mds148","journal-title":"Ann Oncol"},{"key":"2106_CR110","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.tranon.2017.09.007","volume":"10","author":"TM Grzywa","year":"2017","unstructured":"Grzywa TM, Paskal W, W\u0142odarski PK (2017) Intratumor and intertumor heterogeneity in melanoma. Transl Oncol 10:956\u2013975. https:\/\/doi.org\/10.1016\/j.tranon.2017.09.007","journal-title":"Transl Oncol"},{"key":"2106_CR111","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s13045-020-01005-x","volume":"13","author":"M Hong","year":"2020","unstructured":"Hong M, Tao S, Zhang L, Diao LT, Huang X, Huang S, Xie S-J, Xiao Z-D, Zhang H (2020) RNA sequencing: new technologies and applications in cancer research. J Hematol Oncol 13:166. https:\/\/doi.org\/10.1186\/s13045-020-01005-x","journal-title":"J Hematol Oncol"},{"key":"2106_CR112","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.3390\/cancers13081872","volume":"13","author":"HV Jain","year":"2021","unstructured":"Jain HV, Sorribes IC, Handelman SK, Barnaby J, Jackson TL (2021) Standing variations modeling captures inter-individual heterogeneity in a deterministic model of prostate cancer response to combination therapy. Cancer 13:1872","journal-title":"Cancer"},{"key":"2106_CR113","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1126\/science.aad0501","volume":"352","author":"I Tirosh","year":"2016","unstructured":"Tirosh I, Izar B, Prakadan SM, Wadsworth MH, Treacy D, Trombetta JJ, Rotem A, Rodman C, Lian C, Murphy G et al (2016) Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Sci 352:189\u2013196. https:\/\/doi.org\/10.1126\/science.aad0501","journal-title":"Sci"},{"key":"2106_CR114","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.cell.2020.07.017","volume":"182","author":"A Maynard","year":"2020","unstructured":"Maynard A, McCoach CE, Rotow JK, Harris L, Haderk F, Kerr DL, Yu EA, Schenk EL, Tan W, Zee A et al (2020) Therapy-induced evolution of human lung cancer revealed by single-cell RNA sequencing. Cell 182:1232\u20131251. https:\/\/doi.org\/10.1016\/j.cell.2020.07.017","journal-title":"Cell"},{"key":"2106_CR115","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1038\/s41467-018-04724-5","volume":"9","author":"E Berglund","year":"2018","unstructured":"Berglund E, Maaskola J, Schultz N, Friedrich S, Marklund M, Bergenstr\u00e5hle J, Tarish F, Tanoglidi A, Vickovic S, Larsson L et al (2018) Spatial maps of prostate cancer transcriptomes reveal an unexplored landscape of heterogeneity. Nat Commun 9:2419. https:\/\/doi.org\/10.1038\/s41467-018-04724-5","journal-title":"Nat Commun"},{"key":"2106_CR116","doi-asserted-by":"publisher","first-page":"10029","DOI":"10.1073\/pnas.1702697114","volume":"114","author":"L Cardelli","year":"2017","unstructured":"Cardelli L, Tribastone M, Tschaikowski M, Vandin A (2017) Maximal aggregation of polynomial dynamical systems. Proc Natl Acad Sci 114:10029\u201310034. https:\/\/doi.org\/10.1073\/pnas.1702697114","journal-title":"Proc Natl Acad Sci"},{"key":"2106_CR117","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.cels.2018.01.013","volume":"6","author":"Y Ye","year":"2018","unstructured":"Ye Y, Xiang Y, Ozguc FM, Kim Y, Liu C-J, Park PK, Hu Q, Diao L, Lou Y, Lin C et al (2018) The genomic landscape and pharmacogenomic interactions of clock genes in cancer chronotherapy. Cell Syst 6:314\u2013328. https:\/\/doi.org\/10.1016\/j.cels.2018.01.013","journal-title":"Cell Syst"},{"key":"2106_CR118","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.3389\/fimmu.2019.02451","volume":"10","author":"Y Wu","year":"2019","unstructured":"Wu Y, Tao B, Zhang T, Fan Y, Mao R (2019) Pan-cancer analysis reveals disrupted circadian clock associates with T cell exhaustion. Front Immunol 10:2451. https:\/\/doi.org\/10.3389\/fimmu.2019.02451","journal-title":"Front Immunol"},{"key":"2106_CR119","doi-asserted-by":"publisher","unstructured":"Vlachou D, Bjarnason GA, Giacchetti S, L\u00e9vi F, Rand DA (2020) TimeTeller: a new tool for precision circadian medicine and cancer prognosis. bioRxiv 622050. https:\/\/doi.org\/10.1101\/622050","DOI":"10.1101\/622050"},{"issue":"1","key":"2106_CR120","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1007218","volume":"16","author":"RJW Hill","year":"2020","unstructured":"Hill RJW, Innominato PF, L\u00e9vi F, Ballesta A (2020) Optimizing circadian drug infusion schedules towards personalized cancer chronotherapy. PLoS Comput Biol 16(1):e1007218. https:\/\/doi.org\/10.1371\/journal.pcbi.1007218","journal-title":"PLoS Comput Biol"},{"key":"2106_CR121","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.3390\/cancers12113103","volume":"12","author":"J Hesse","year":"2020","unstructured":"Hesse J, Malhan D, Yal\u04abin M, Aboumanify O, Basti A, Rel\u00f3gio A (2020) An optimal time for treatment predicting circadian time by machine learning and mathematical modelling. Cancer 12:3103","journal-title":"Cancer"},{"key":"2106_CR122","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1146\/annurev-pharmtox-011613-135923","volume":"54","author":"R Dallmann","year":"2014","unstructured":"Dallmann R, Brown SA, Gachon F (2014) Chronopharmacology: new insights and therapeutic implications. Annu Rev Pharmacol Toxicol 54:339\u2013361. https:\/\/doi.org\/10.1146\/annurev-pharmtox-011613-135923","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2106_CR123","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1146\/annurev.pharmtox.48.113006.094626","volume":"50","author":"F Levi","year":"2010","unstructured":"Levi F, Okyar A, Dulong S, Innominato PF, Clairambault J (2010) Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol 50:377\u2013421. https:\/\/doi.org\/10.1146\/annurev.pharmtox.48.113006.094626","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"2","key":"2106_CR124","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1517\/17425255.4.2.175","volume":"4","author":"M Baraldo","year":"2008","unstructured":"Baraldo M (2008) The influence of circadian rhythms on the kinetics of drugs in humans. Expert Opin Drug Metab Toxicol 4(2):175\u2013192. https:\/\/doi.org\/10.1517\/17425255.4.2.175","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2106_CR125","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1111\/j.1440-1681.2009.05254.x","volume":"36","author":"R Bron","year":"2009","unstructured":"Bron R, Furness JB (2009) Rhythm of digestion: keeping time in the gastrointestinal tract. Clin Exp Pharmacol Physiol 36:1041\u20131048. https:\/\/doi.org\/10.1111\/j.1440-1681.2009.05254.x","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2106_CR126","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1194\/jlr.M900085-JLR200","volume":"50","author":"X Pan","year":"2009","unstructured":"Pan X, Hussain MM (2009) Clock is important for food and circadian regulation of macronutrient absorption in mice. J Lipid Res 50:1800\u20131813. https:\/\/doi.org\/10.1194\/jlr.M900085-JLR200","journal-title":"J Lipid Res"},{"issue":"1","key":"2106_CR127","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1161\/01.hyp.33.1.248","volume":"33","author":"NH Anderson","year":"1999","unstructured":"Anderson NH, Devlin AM, Graham D, Morton JJ, Hamilton CA, Reid JL, Schork NJ, Dominiczak AF (1999) Telemetry for cardiovascular monitoring in a pharmacological study: new approaches to data analysis. Hypertens 33(1):248\u2013255. https:\/\/doi.org\/10.1161\/01.hyp.33.1.248","journal-title":"Hypertens"},{"key":"2106_CR128","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.addr.2010.06.002","volume":"62","author":"PF Innominato","year":"2010","unstructured":"Innominato PF, Levi FA, Bjarnason GA (2010) Chronotherapy and the molecular clock: Clinical implications in oncology. Adv Drug Deliv Rev 62:979\u20131001. https:\/\/doi.org\/10.1016\/j.addr.2010.06.002","journal-title":"Adv Drug Deliv Rev"},{"key":"2106_CR129","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2133\/dmpk.dmpk-10-rv-089","volume":"26","author":"TA Baillie","year":"2011","unstructured":"Baillie TA, Rettie AE (2011) Role of biotransformation in drug-induced toxicity: influence of intra- and inter-species differences in drug metabolism. Drug Metab Pharmacokinet 26:15\u201329. https:\/\/doi.org\/10.2133\/dmpk.dmpk-10-rv-089","journal-title":"Drug Metab Pharmacokinet"},{"key":"2106_CR130","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1517\/17425255.2011.544251","volume":"7","author":"F Gachon","year":"2011","unstructured":"Gachon F, Firsov D (2011) The role of circadian timing system on drug metabolism and detoxification. Expert Opin Drug Metab Toxicol 7:147\u2013158. https:\/\/doi.org\/10.1517\/17425255.2011.544251","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2106_CR131","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1021\/tx200538r","volume":"25","author":"UP Zmrzljak","year":"2012","unstructured":"Zmrzljak UP, Rozman D (2012) Circadian regulation of the hepatic endobiotic and xenobitoic detoxification pathways: the time matters. Chem Res Toxicol 25:811\u2013824. https:\/\/doi.org\/10.1021\/tx200538r","journal-title":"Chem Res Toxicol"},{"key":"2106_CR132","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2217\/14622416.8.3.257","volume":"8","author":"X Zhang","year":"2007","unstructured":"Zhang X, Diasio RB (2007) Regulation of human dihydropyrimidine dehydrogenase: implications in the pharmacogenetics of 5-FU-based chemotherapy. Pharmacogenomics 8:257\u2013265. https:\/\/doi.org\/10.2217\/14622416.8.3.257","journal-title":"Pharmacogenomics"},{"key":"2106_CR133","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1254\/jphs.08100sc","volume":"108","author":"AT Stearns","year":"2008","unstructured":"Stearns AT, Balakrishnan A, Rhoads DB, Ashley SW, Tavakkolizadeh A (2008) Diurnal rhythmicity in the transcription of jejunal drug transporters. J Pharmacol Sci 108:144\u2013148. https:\/\/doi.org\/10.1254\/jphs.08100sc","journal-title":"J Pharmacol Sci"},{"key":"2106_CR134","doi-asserted-by":"publisher","unstructured":"Doi M, Takahashi Y, Komatsu R, Yamazaki F, Yamada H, Haraguchi S, Emoto N, Okuno Y, Tsujimoto G, Kanematsu A et al (2010) Salt-sensitive hypertension in circadian clock-deficient Cry-null mice involves dysregulated adrenal Hsd3b6. Nat Med 16:67\u201374. https:\/\/doi.org\/10.1038\/nm.2061","DOI":"10.1038\/nm.2061"},{"key":"2106_CR135","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1158\/1535-7163.mct-15-0129","volume":"14","author":"S Dulong","year":"2015","unstructured":"Dulong S, Ballesta A, Okyar A, L\u00e9vi F (2015) Identification of circadian determinants of cancer chronotherapy through in vitro chronopharmacology and mathematical modeling. Mol Cancer Ther 14:2154\u20132164. https:\/\/doi.org\/10.1158\/1535-7163.mct-15-0129","journal-title":"Mol Cancer Ther"},{"key":"2106_CR136","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jconrel.2014.03.054","volume":"190","author":"K Park","year":"2014","unstructured":"Park K (2014) Controlled drug delivery systems: past forward and future back. J Control Release 190:3\u20138. https:\/\/doi.org\/10.1016\/j.jconrel.2014.03.054","journal-title":"J Control Release"},{"key":"2106_CR137","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1124\/pr.116.013441","volume":"69","author":"A Ballesta","year":"2017","unstructured":"Ballesta A, Innominato PF, Dallmann R, Rand DA, Levi FA (2017) Systems chronotherapeutics. Pharmacol Rev 69:161\u2013199. https:\/\/doi.org\/10.1124\/pr.116.013441","journal-title":"Pharmacol Rev"},{"issue":"7","key":"2106_CR138","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3390\/pharmaceutics11070302","volume":"11","author":"F Ketabat","year":"2019","unstructured":"Ketabat F, Pundir M, Mohabatpour F, Lobanova L, Koutsopoulos S, Hadjiiski L, Chen X, Papagerakis P, Papagerakis S (2019) Controlled drug delivery systems for oral cancer treatment-current status and future perspectives. Pharmaceutics 11(7):302. https:\/\/doi.org\/10.3390\/pharmaceutics11070302","journal-title":"Pharmaceutics"},{"key":"2106_CR139","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40262-016-0431-2","volume":"56","author":"F L\u00e9vi","year":"2017","unstructured":"L\u00e9vi F, Karabou\u00e9 A, Etienne-Grimaldi MC, Paintaud G, Focan C, Innominato P, Bouchahda M, Milano G, Chatelut E (2017) Pharmacokinetics of irinotecan oxaliplatin and 5-fluorouracil during hepatic artery chronomodulated infusion: a translational European OPTILIV study. Clin Pharmacokinet 56:165\u2013177. https:\/\/doi.org\/10.1007\/s40262-016-0431-2","journal-title":"Clin Pharmacokinet"},{"key":"2106_CR140","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2019.110610","volume":"185","author":"AR Neves","year":"2020","unstructured":"Neves AR, Sousa A, Faria R, Albuquerque T, Queiroz JA, Costa D (2020) Cancer gene therapy mediated by RALA\/plasmid DNA vectors: nitrogen to phosphate groups ratio (N\/P) as a tool for tunable transfection efficiency and apoptosis. Colloids Surf B 185:110610. https:\/\/doi.org\/10.1016\/j.colsurfb.2019.110610","journal-title":"Colloids Surf B"},{"key":"2106_CR141","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.colsurfb.2018.06.063","volume":"170","author":"D Costa","year":"2018","unstructured":"Costa D, Valente AJM, Queiroz JA, Sousa \u00c2 (2018) Finding the ideal polyethylenimine-plasmid DNA system for co-delivery of payloads in cancer therapy. Colloids Surf B 170:627\u2013636. https:\/\/doi.org\/10.1016\/j.colsurfb.2018.06.063","journal-title":"Colloids Surf B"},{"key":"2106_CR142","doi-asserted-by":"publisher","DOI":"10.1016\/j.molliq.2019.111391","volume":"292","author":"R Faria","year":"2019","unstructured":"Faria R, Sousa \u00c2, Neves AR, Queiroz JA, Costa D (2019) Methotrexate-plasmid DNA polyplexes for cancer therapy: characterization, cancer cell targeting ability and tuned in vitro transfection. J Mol Liq 292:111391. https:\/\/doi.org\/10.1016\/j.molliq.2019.111391","journal-title":"J Mol Liq"},{"key":"2106_CR143","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.7150\/thno.23459","volume":"8","author":"W Wu","year":"2018","unstructured":"Wu W, Luo L, Wang Y, Wu Q, Dai HB, Li JS, Durkan C, Wang N, Wang GX (2018) Endogenous pH-responsive nanoparticles with programmable size changes for targeted tumor therapy and imaging applications. Theranostics 8:3038\u20133058. https:\/\/doi.org\/10.7150\/thno.23459","journal-title":"Theranostics"},{"key":"2106_CR144","doi-asserted-by":"publisher","first-page":"14447","DOI":"10.1038\/s41598-020-71071-1","volume":"10","author":"M Chen","year":"2020","unstructured":"Chen M, Hu J, Wang L, Li Y, Zhu C, Chen C, Shi M, Ju Z, Cao X, Zhang Z (2020) Targeted and redox-responsive drug delivery systems based on carbonic anhydrase IX-decorated mesoporous silica nanoparticles for cancer therapy. Sci Rep 10:14447. https:\/\/doi.org\/10.1038\/s41598-020-71071-1","journal-title":"Sci Rep"},{"issue":"1","key":"2106_CR145","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/molecules24010004","volume":"24","author":"H Tang","year":"2018","unstructured":"Tang H, Zhao W, Yu J, Li Y, Zhao C (2018) Recent development of pH-responsive polymers for cancer nanomedicine. Molecules 24(1):4. https:\/\/doi.org\/10.3390\/molecules24010004","journal-title":"Molecules"},{"issue":"10","key":"2106_CR146","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3390\/pharmaceutics11100543","volume":"11","author":"OK Nag","year":"2019","unstructured":"Nag OK, Delehanty JB (2019) Active cellular and subcellular targeting of nanoparticles for drug delivery. Pharmaceutics 11(10):543. https:\/\/doi.org\/10.3390\/pharmaceutics11100543","journal-title":"Pharmaceutics"},{"key":"2106_CR147","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-020-00342-0","volume":"5","author":"X Fu","year":"2020","unstructured":"Fu X, Shi Y, Qi T, Qiu S, Huang Y, Zhao X, Sun Q, Lin G (2020) Precise design strategies of nanomedicine for improving cancer therapeutic efficacy using subcellular targeting. Signal Transduct Target Ther 5:262. https:\/\/doi.org\/10.1038\/s41392-020-00342-0","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"2106_CR148","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.3390\/molecules24061035","volume":"24","author":"J Pan","year":"2019","unstructured":"Pan J, Rostamizadeh K, Filipczak N, Torchilin VP (2019) Polymeric co-delivery systems in cancer treatment: an overview on component drugs\u2019 dosage ratio effect. Molecules 24(6):1035. https:\/\/doi.org\/10.3390\/molecules24061035","journal-title":"Molecules"},{"issue":"20","key":"2106_CR149","doi-asserted-by":"publisher","first-page":"16793","DOI":"10.1021\/acsami.7b01540","volume":"9","author":"WQ Li","year":"2017","unstructured":"Li WQ, Wang Z, Hao S, He H, Wan Y, Zhu C, Sun LP, Cheng G, Zheng SY (2017) Mitochondria-targeting polydopamine nanoparticles to deliver doxorubicin for overcoming drug resistance. ACS Appl Mater Interfaces 9(20):16793\u201316802. https:\/\/doi.org\/10.1021\/acsami.7b01540","journal-title":"ACS Appl Mater Interfaces"},{"key":"2106_CR150","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.biopha.2018.12.008","volume":"110","author":"K Vinothini","year":"2019","unstructured":"Vinothini K, Rajendran NK, Ramu A, Elumalai N, Rajan M (2019) Folate receptor targeted delivery of paclitaxel to breast cancer cells via folic acid conjugated graphene oxide grafted methyl acrylate nanocarrier. Biomed Pharmacother 110:906\u2013917. https:\/\/doi.org\/10.1016\/j.biopha.2018.12.008","journal-title":"Biomed Pharmacother"},{"key":"2106_CR151","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1208\/s12249-020-01672-6","volume":"21","author":"AM Mohammed","year":"2020","unstructured":"Mohammed AM, Osman SK, Saleh KI, Samy AM (2020) In vitro release of 5-fluorouracil and methotrexate from different thermosensitive chitosan hydrogel systems. AAPS PharmSciTech 21:131. https:\/\/doi.org\/10.1208\/s12249-020-01672-6","journal-title":"AAPS PharmSciTech"},{"issue":"26","key":"2106_CR152","doi-asserted-by":"publisher","first-page":"22214","DOI":"10.1021\/acsomega.9b03594","volume":"4","author":"A Angelopoulou","year":"2019","unstructured":"Angelopoulou A, Kolokithas-Ntoukas A, Fytas C, Avgoustakis K (2019) Folic acid-functionalized condensed magnetic nanoparticles for targeted delivery of doxorubicin to tumor cancer cells overexpressing the folate receptor. ACS Omega 4(26):22214\u201322227. https:\/\/doi.org\/10.1021\/acsomega.9b03594","journal-title":"ACS Omega"},{"key":"2106_CR153","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12951-018-0398-2","volume":"16","author":"X Guo","year":"2018","unstructured":"Guo X, Cheng Y, Zhao X, Luo Y, Chen J, Yuan W-E (2018) Advances in redox-responsive drug delivery systems of tumor microenvironment. J Nanobiotechnology 16:74. https:\/\/doi.org\/10.1186\/s12951-018-0398-2","journal-title":"J Nanobiotechnology"},{"key":"2106_CR154","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12951-019-0562-3","volume":"18","author":"H Wang","year":"2020","unstructured":"Wang H, Zhang F, Wen H, Shi W, Huang Q, Huang Y, Xie J, Li P, Chen J, Qin L et al (2020) Tumor- and mitochondria-targeted nanoparticles eradicate drug resistant lung cancer through mitochondrial pathway of apoptosis. J Nanobiotechnology 18:8. https:\/\/doi.org\/10.1186\/s12951-019-0562-3","journal-title":"J Nanobiotechnology"},{"key":"2106_CR155","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1477-3155-12-5","volume":"12","author":"L Shang","year":"2014","unstructured":"Shang L, Nienhaus K, Nienhaus GU (2014) Engineered nanoparticles interacting with cells: size matters. J Nanobiotechnology 12:5. https:\/\/doi.org\/10.1186\/1477-3155-12-5","journal-title":"J Nanobiotechnology"},{"key":"2106_CR156","volume-title":"Characterization of nanoparticles intended for drug delivery","author":"JD Clogston","year":"2011","unstructured":"Clogston JD, Patri AK (2011) Characterization of nanoparticles intended for drug delivery. Humana Press, New York"},{"key":"2106_CR157","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3389\/fmolb.2020.587012","volume":"7","author":"G Sanit\u00e0","year":"2020","unstructured":"Sanit\u00e0 G, Carrese B, Lamberti A (2020) Nanoparticle surface functionalization: how to improve biocompatibility and cellular internalization. Front Mol Biosci 7:381","journal-title":"Front Mol Biosci"},{"key":"2106_CR158","doi-asserted-by":"publisher","first-page":"723","DOI":"10.2174\/1389200219666171207120643","volume":"19","author":"J Hu","year":"2018","unstructured":"Hu J, Sheng Y, Shi J, Yu B, Yu Z, Liao G (2018) Long circulating polymeric nanoparticles for gene\/drug delivery. Curr Drug Metab 19:723\u2013738. https:\/\/doi.org\/10.2174\/1389200219666171207120643","journal-title":"Curr Drug Metab"},{"issue":"9","key":"2106_CR159","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1080\/10717544.2016.1177136","volume":"23","author":"C Zylberberg","year":"2016","unstructured":"Zylberberg C, Matosevic S (2016) Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape. Drug Deliv 23(9):3319\u20133329. https:\/\/doi.org\/10.1080\/10717544.2016.1177136","journal-title":"Drug Deliv"},{"key":"2106_CR160","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1124\/jpet.118.254797","volume":"370","author":"M Das","year":"2019","unstructured":"Das M, Huang L (2019) Liposomal nanostructures for drug delivery in gastrointestinal cancers. J Pharmacol Exp Ther 370:647\u2013656. https:\/\/doi.org\/10.1124\/jpet.118.254797","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"2106_CR161","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1039\/C9MD00459A","volume":"11","author":"W Radchatawedchakoon","year":"2020","unstructured":"Radchatawedchakoon W, Thongbamrer C, Konbamrung W, Khattawee P, Sakee U, Roobsoong W, Sattabongkot J, Opanasopit P, Yingyongnarongkul BE (2020) The effect of polar headgroups and spacer length on the DNA transfection of cholesterol-based cationic lipids. RSC Med Chem 11(2):212\u2013224. https:\/\/doi.org\/10.1039\/C9MD00459A","journal-title":"RSC Med Chem"},{"key":"2106_CR162","doi-asserted-by":"publisher","first-page":"7035","DOI":"10.2147\/ijn.s255902","volume":"15","author":"MS Ashrafzadeh","year":"2020","unstructured":"Ashrafzadeh MS, Akbarzadeh A, Heydarinasab A, Ardjmand M (2020) In vivo glioblastoma therapy using targeted liposomal cisplatin. Int J Nanomedicine 15:7035\u20137049. https:\/\/doi.org\/10.2147\/ijn.s255902","journal-title":"Int J Nanomedicine"},{"issue":"11","key":"2106_CR163","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.3390\/nano10112104","volume":"10","author":"E Redolfi Riva","year":"2020","unstructured":"Redolfi Riva E, Sinibaldi E, Grillone AF, Del Turco S, Mondini A, Li T, Takeoka S, Mattoli V (2020) Enhanced in vitro magnetic cell targeting of doxorubicin-loaded magnetic liposomes for localized cancer therapy. Nanomaterials 10(11):2104. https:\/\/doi.org\/10.3390\/nano10112104","journal-title":"Nanomaterials"},{"key":"2106_CR164","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.120117","volume":"593","author":"V Makwana","year":"2021","unstructured":"Makwana V, Karanjia J, Haselhorst T, Anoopkumar-Dukie S, Rudrawar S (2021) Liposomal doxorubicin as targeted delivery platform: current trends in surface functionalization. Int J Pharm 593:120117. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.120117","journal-title":"Int J Pharm"},{"issue":"2","key":"2106_CR165","doi-asserted-by":"publisher","first-page":"559","DOI":"10.3390\/ijms21020559","volume":"21","author":"M Ghaferi","year":"2020","unstructured":"Ghaferi M, Asadollahzadeh MJ, Akbarzadeh A, Ebrahimi Shahmabadi H, Alavi SE (2020) Enhanced efficacy of PEGylated liposomal cisplatin: in vitro and in vivo evaluation. Int J Mol Sci 21(2):559. https:\/\/doi.org\/10.3390\/ijms21020559","journal-title":"Int J Mol Sci"},{"issue":"20","key":"2106_CR166","doi-asserted-by":"publisher","first-page":"11573","DOI":"10.1039\/C9RA09040A","volume":"10","author":"G Yue","year":"2020","unstructured":"Yue G, Wang C, Liu B, Wu M, Huang Y, Guo Y, Ma Q (2020) Liposomes co-delivery system of doxorubicin and astragaloside IV co-modified by folate ligand and octa-arginine polypeptide for anti-breast cancer. RSC Adv 10(20):11573\u201311581. https:\/\/doi.org\/10.1039\/C9RA09040A","journal-title":"RSC Adv"},{"key":"2106_CR167","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/08982104.2019.1634724","volume":"30","author":"KS Ahmed","year":"2020","unstructured":"Ahmed KS, Changling S, Shan X, Mao J, Qiu L, Chen J (2020) Liposome-based codelivery of celecoxib and doxorubicin hydrochloride as a synergistic dual-drug delivery system for enhancing the anticancer effect. J Liposome Res 30:285\u2013296. https:\/\/doi.org\/10.1080\/08982104.2019.1634724","journal-title":"J Liposome Res"},{"key":"2106_CR168","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1080\/10717544.2020.1772409","volume":"27","author":"C Du","year":"2020","unstructured":"Du C, Li S, Li Y, Galons H, Guo N, Teng Y, Zhang Y, Li M, Yu P (2020) F7 and topotecan co-loaded thermosensitive liposome as a nano-drug delivery system for tumor hyperthermia. Drug Deliv 27:836\u2013847. https:\/\/doi.org\/10.1080\/10717544.2020.1772409","journal-title":"Drug Deliv"},{"key":"2106_CR169","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.ijpharm.2018.09.019","volume":"551","author":"ET Sarcan","year":"2018","unstructured":"Sarcan ET, Silindir-Gunay M, Ozer AY (2018) Theranostic polymeric nanoparticles for NIR imaging and photodynamic therapy. Int J Pharm 551:329\u2013338. https:\/\/doi.org\/10.1016\/j.ijpharm.2018.09.019","journal-title":"Int J Pharm"},{"issue":"11","key":"2106_CR170","doi-asserted-by":"publisher","first-page":"7789","DOI":"10.1021\/acsabm.0c00974","volume":"3","author":"I Khan","year":"2020","unstructured":"Khan I, Joshi G, Sarkar B, Nakhate KT, Ajazuddin MAK, Kumar R, Kaul A, Chaturvedi S, Mishra AK et al (2020) Doxorubicin and Crocin co-delivery by polymeric nanoparticles for enhanced anticancer potential in vitro and in vivo. ACS Appl Bio Mater 3(11):7789\u20137799. https:\/\/doi.org\/10.1021\/acsabm.0c00974","journal-title":"ACS Appl Bio Mater"},{"key":"2106_CR171","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.601626","volume":"12","author":"A Gagliardi","year":"2021","unstructured":"Gagliardi A, Giuliano E, Venkateswararao E, Fresta M, Bulotta S, Awasthi V, Cosco D (2021) Biodegradable polymeric nanoparticles for drug delivery to solid tumors. Front Pharmacol 12:601626. https:\/\/doi.org\/10.3389\/fphar.2021.601626","journal-title":"Front Pharmacol"},{"key":"2106_CR172","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117943","volume":"256","author":"F Madani","year":"2020","unstructured":"Madani F, Esnaashari SS, Bergonzi MC, Webster TJ, Younes HM, Khosravani M, Adabi M (2020) Paclitaxel\/methotrexate co-loaded PLGA nanoparticles in glioblastoma treatment: formulation development and in vitro antitumor activity evaluation. Life Sci 256:117943. https:\/\/doi.org\/10.1016\/j.lfs.2020.117943","journal-title":"Life Sci"},{"key":"2106_CR173","doi-asserted-by":"publisher","first-page":"7271","DOI":"10.1166\/jnn.2020.18608","volume":"20","author":"Y Fu","year":"2020","unstructured":"Fu Y, Tan L, Meng L, Lei X (2020) Therapeutic effects of paclitaxel loaded polyethylene glycol-polylactic acid-glycolic acid copolymer nanoparticles on pancreatic cancer in rats. J Nanosci Nanotechnol 20:7271\u20137275. https:\/\/doi.org\/10.1166\/jnn.2020.18608","journal-title":"J Nanosci Nanotechnol"},{"key":"2106_CR174","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s12221-020-1095-y","volume":"21","author":"S Gooneh-Farahani","year":"2020","unstructured":"Gooneh-Farahani S, Naghib SM, Naimi-Jamal MR (2020) A novel and inexpensive method based on modified ionic gelation for pH-responsive controlled drug release of homogeneously distributed chitosan nanoparticles with a high encapsulation efficiency. Fibers Polym 21:1917\u20131926. https:\/\/doi.org\/10.1007\/s12221-020-1095-y","journal-title":"Fibers Polym"},{"key":"2106_CR175","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.2147\/ijn.s302238","volume":"16","author":"HI Chiu","year":"2021","unstructured":"Chiu HI, Lim V (2021) Wheat germ agglutinin-conjugated disulfide cross-linked alginate nanoparticles as a docetaxel carrier for colon cancer therapy. Int J Nanomedicine 16:2995\u20133020. https:\/\/doi.org\/10.2147\/ijn.s302238","journal-title":"Int J Nanomedicine"},{"key":"2106_CR176","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12938-019-0624-7","volume":"18","author":"N Qu","year":"2019","unstructured":"Qu N, Sun Y, Li Y, Hao F, Qiu P, Teng L, Xie J, Gao Y (2019) Docetaxel-loaded human serum albumin (HSA) nanoparticles: synthesis characterization and evaluation. Biomed Eng Online 18:11. https:\/\/doi.org\/10.1186\/s12938-019-0624-7","journal-title":"Biomed Eng Online"},{"key":"2106_CR177","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/905091","volume":"2013","author":"I Cucinotto","year":"2013","unstructured":"Cucinotto I, Fiorillo L, Gualtieri S, Arbitrio M, Ciliberto D, Staropoli N, Grimaldi A, Luce A, Tassone P, Caraglia M et al (2013) Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time? J Drug Deliv 2013:905091. https:\/\/doi.org\/10.1155\/2013\/905091","journal-title":"J Drug Deliv"},{"key":"2106_CR178","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1080\/21691401.2018.1470527","volume":"46","author":"SVK Rompicharla","year":"2018","unstructured":"Rompicharla SVK, Kumari P, Ghosh B, Biswas S (2018) Octa-arginine modified poly(amidoamine) dendrimers for improved delivery and cytotoxic effect of paclitaxel in cancer. Artif Cell Nanomed Biotechnol 46:847\u2013859. https:\/\/doi.org\/10.1080\/21691401.2018.1470527","journal-title":"Artif Cell Nanomed Biotechnol"},{"key":"2106_CR179","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1021\/acsabm.0c00179","volume":"3","author":"H Bhatt","year":"2020","unstructured":"Bhatt H, Ghosh B, Biswas S (2020) Cell-penetrating peptide and \u03b1-tocopherol-conjugated poly(amidoamine) dendrimers for improved delivery and anticancer activity of loaded paclitaxel. ACS Appl Bio Mater 3:3157\u20133169. https:\/\/doi.org\/10.1021\/acsabm.0c00179","journal-title":"ACS Appl Bio Mater"},{"issue":"6","key":"2106_CR180","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1039\/C9TB02289A","volume":"8","author":"MR Carvalho","year":"2020","unstructured":"Carvalho MR, Reis RL, Oliveira JM (2020) Dendrimer nanoparticles for colorectal cancer applications. J Mater Chem B 8(6):1128\u20131138. https:\/\/doi.org\/10.1039\/C9TB02289A","journal-title":"J Mater Chem B"},{"key":"2106_CR181","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.2147\/ijn.s243155","volume":"15","author":"M Fana","year":"2020","unstructured":"Fana M, Gallien J, Srinageshwar B, Dunbar GL, Rossignol J (2020) PAMAM dendrimer nanomolecules utilized as drug delivery systems for potential treatment of glioblastoma: a systematic review. Int J Nanomedicine 15:2789\u20132808. https:\/\/doi.org\/10.2147\/ijn.s243155","journal-title":"Int J Nanomedicine"},{"key":"2106_CR182","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/bit.27645","volume":"118","author":"R Anbazhagan","year":"2021","unstructured":"Anbazhagan R, Muthusamy G, Krishnamoorthi R, Kumaresan S, Rajendra Prasad N, Lai JY, Yang JM, Tsai HC (2021) PAMAM G4.5 dendrimers for targeted delivery of ferulic acid and paclitaxel to overcome P-glycoprotein-mediated multidrug resistance. Biotechnol Bioeng 118:1213\u20131223. https:\/\/doi.org\/10.1002\/bit.27645","journal-title":"Biotechnol Bioeng"},{"key":"2106_CR183","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1039\/C9SC06497D","volume":"11","author":"J Zhang","year":"2020","unstructured":"Zhang J, Mou L, Jiang X (2020) Surface chemistry of gold nanoparticles for health-related applications. Chem Sci 11:923\u2013936. https:\/\/doi.org\/10.1039\/C9SC06497D","journal-title":"Chem Sci"},{"key":"2106_CR184","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1259\/bjr\/59448833","volume":"85","author":"S Jain","year":"2012","unstructured":"Jain S, Hirst DG, O\u2019Sullivan JM (2012) Gold nanoparticles as novel agents for cancer therapy. Br J Radiol 85:101\u2013113. https:\/\/doi.org\/10.1259\/bjr\/59448833","journal-title":"Br J Radiol"},{"key":"2106_CR185","doi-asserted-by":"publisher","DOI":"10.1016\/j.sciaf.2020.e00685","volume":"11","author":"M Yafout","year":"2021","unstructured":"Yafout M, Ousaid A, Khayati Y, El Otmani IS (2021) Gold nanoparticles as a drug delivery system for standard chemotherapeutics: a new lead for targeted pharmacological cancer treatments. Sci Afr 11:e00685. https:\/\/doi.org\/10.1016\/j.sciaf.2020.e00685","journal-title":"Sci Afr"},{"key":"2106_CR186","doi-asserted-by":"publisher","first-page":"10255","DOI":"10.1039\/D0CC01325K","volume":"56","author":"M Nerantzaki","year":"2020","unstructured":"Nerantzaki M, Michel A, Briot E, Siaugue JM, M\u00e9nager C, Wilhelm C, Griffete N (2020) Controlled drug delivery for cancer cell treatment via magnetic doxorubicin imprinted silica nanoparticles. Chem Commun 56:10255\u201310258. https:\/\/doi.org\/10.1039\/D0CC01325K","journal-title":"Chem Commun"},{"key":"2106_CR187","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119576","volume":"586","author":"Z Li","year":"2020","unstructured":"Li Z, Zhang Y, Zhu C, Guo T, Xia Q, Hou X, Liu W, Feng N (2020) Folic acid modified lipid-bilayer coated mesoporous silica nanoparticles co-loading paclitaxel and tanshinone IIA for the treatment of acute promyelocytic leukemia. Int J Pharm 586:119576. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.119576","journal-title":"Int J Pharm"},{"issue":"2","key":"2106_CR188","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3390\/pharmaceutics13020152","volume":"13","author":"ED Mohamed Isa","year":"2021","unstructured":"Mohamed Isa ED, Ahmad H, Abdul Rahman MB, Gill MR (2021) Progress in mesoporous silica nanoparticles as drug delivery agents for cancer treatment. Pharmaceutics 13(2):152. https:\/\/doi.org\/10.3390\/pharmaceutics13020152","journal-title":"Pharmaceutics"},{"key":"2106_CR189","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2019.110576","volume":"109","author":"S Godara","year":"2020","unstructured":"Godara S, Lather V, Kirthanashri SV, Awasthi R, Pandita D (2020) Lipid-PLGA hybrid nanoparticles of paclitaxel: preparation characterization in vitro and in vivo evaluation. Mater Sci Eng C 109:110576. https:\/\/doi.org\/10.1016\/j.msec.2019.110576","journal-title":"Mater Sci Eng C"},{"key":"2106_CR190","doi-asserted-by":"publisher","unstructured":"Persano F, Gigli G, Leporatti S (2021) Lipid-polymer hybrid nanoparticles in cancer therapy: current overview and future directions. Nano Express 2. https:\/\/doi.org\/10.1088\/2632-959X\/abeb4b","DOI":"10.1088\/2632-959X\/abeb4b"},{"issue":"5","key":"2106_CR191","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1124\/dmd.120.090472","volume":"48","author":"D Lu","year":"2020","unstructured":"Lu D, Zhao M, Chen M, Wu B (2020) Circadian clock-controlled drug metabolism: implications for chronotherapeutics. Drug Metab Dispos 48(5):395\u2013406. https:\/\/doi.org\/10.1124\/dmd.120.090472","journal-title":"Drug Metab Dispos"},{"key":"2106_CR192","doi-asserted-by":"publisher","unstructured":"Lee Y, Fong SY, Shon J, Zhang SL, Brooks R, Lahens NF, Chen D, Dang CV, Field JM, Sehgal A (2021) Time-of-day specificity of anticancer drugs may be mediated by circadian regulation of the cell cycle. Sci Adv 7(7):eabd2645. https:\/\/doi.org\/10.1126\/sciadv.abd2645","DOI":"10.1126\/sciadv.abd2645"},{"key":"2106_CR193","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00280-016-3067-x","volume":"78","author":"KN Pilanc\u0131","year":"2016","unstructured":"Pilanc\u0131 KN, Saglam S, Okyar A, Yucel S, Pala-Kara Z, Ordu C, Namal E, Ciftci R, Iner-Koksal U, Kaytan-Saglam E (2016) Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: a Phase II Brunch regimen study. Cancer Chemother Pharmacol 78:143\u2013150. https:\/\/doi.org\/10.1007\/s00280-016-3067-x","journal-title":"Cancer Chemother Pharmacol"},{"key":"2106_CR194","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1080\/07420528.2017.1392551","volume":"35","author":"Y Tsuchiya","year":"2018","unstructured":"Tsuchiya Y, Ushijima K, Noguchi T, Okada N, Hayasaka JI, Jinbu Y, Ando H, Mori Y, Kusama M, Fujimura A (2018) Influence of a dosing-time on toxicities induced by docetaxel cisplatin and 5-fluorouracil in patients with oral squamous cell carcinoma a cross-over pilot study. Chronobiol Int 35:289\u2013294. https:\/\/doi.org\/10.1080\/07420528.2017.1392551","journal-title":"Chronobiol Int"},{"key":"2106_CR195","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1517\/13543776.2014.916281","volume":"24","author":"SS Patil","year":"2014","unstructured":"Patil SS, Shahiwala A (2014) Patented pulsatile drug delivery technologies for chronotherapy. Expert Opin Ther Pat 24:845\u2013856. https:\/\/doi.org\/10.1517\/13543776.2014.916281","journal-title":"Expert Opin Ther Pat"},{"key":"2106_CR196","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.addr.2010.04.010","volume":"62","author":"BB Youan","year":"2010","unstructured":"Youan BB (2010) Chronopharmaceutical drug delivery systems: hurdles hype or hope? Adv Drug Deliv Rev 62:898\u2013903. https:\/\/doi.org\/10.1016\/j.addr.2010.04.010","journal-title":"Adv Drug Deliv Rev"},{"key":"2106_CR197","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ijpharm.2016.11.047","volume":"516","author":"J Hu","year":"2017","unstructured":"Hu J, Fu S, Peng Q, Han Y, Xie J, Zan N, Chen Y, Fan J (2017) Paclitaxel-loaded polymeric nanoparticles combined with chronomodulated chemotherapy on lung cancer: In vitro and in vivo evaluation. Int J Pharm 516:313\u2013322. https:\/\/doi.org\/10.1016\/j.ijpharm.2016.11.047","journal-title":"Int J Pharm"},{"key":"2106_CR198","doi-asserted-by":"publisher","first-page":"6238","DOI":"10.1158\/0008-5472.can-10-0184","volume":"70","author":"F Okazaki","year":"2010","unstructured":"Okazaki F, Matsunaga N, Okazaki H, Utoguchi N, Suzuki R, Maruyama K, Koyanagi S, Ohdo S (2010) Circadian rhythm of transferrin receptor 1 gene expression controlled by c-Myc in colon cancer-bearing mice. Cancer Res 70:6238\u20136246. https:\/\/doi.org\/10.1158\/0008-5472.can-10-0184","journal-title":"Cancer Res"},{"key":"2106_CR199","doi-asserted-by":"publisher","first-page":"10505","DOI":"10.1038\/s41598-019-46977-0","volume":"9","author":"A Okyar","year":"2019","unstructured":"Okyar A, Kumar SA, Filipski E, Piccolo E, Ozturk N, Xandri-Monje H, Pala Z, Abraham K, Gomes A, Orman MN et al (2019) Sex- feeding- and circadian time-dependency of P-glycoprotein expression and activity - implications for mechanistic pharmacokinetics modeling. Sci Rep 9:10505. https:\/\/doi.org\/10.1038\/s41598-019-46977-0","journal-title":"Sci Rep"},{"issue":"7","key":"2106_CR200","doi-asserted-by":"publisher","first-page":"988","DOI":"10.3390\/cancers11070988","volume":"11","author":"L Fuhr","year":"2019","unstructured":"Fuhr L, Abreu M, Carbone A, El-Athman R, Bianchi F, Laukkanen MO, Mazzoccoli G, Relogio A (2019) The interplay between colon cancer cells and tumour-associated stromal cells impacts the biological clock and enhances malignant phenotypes. Cancers 11(7):988. https:\/\/doi.org\/10.3390\/cancers11070988","journal-title":"Cancers"},{"key":"2106_CR201","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/clpt.1985.15","volume":"37","author":"F Levi","year":"1985","unstructured":"Levi F, Le Louarn C, Reinberg A (1985) Timing optimizes sustained-release indomethacin treatment of osteoarthritis. Clin Pharmacol Ther 37:77\u201384. https:\/\/doi.org\/10.1038\/clpt.1985.15","journal-title":"Clin Pharmacol Ther"},{"key":"2106_CR202","first-page":"362","volume":"23","author":"B Perpoint","year":"1995","unstructured":"Perpoint B, Le Bousse-Kerdiles C, Clay D, Smadja-Joffe F, Depres-Brummer P, Laporte-simitsidis S, Jasmin C, Levi F (1995) In vitro chronopharmacology of recombinant mouse IL-3 mouse GM-CSF and human G-CSF on murine myeloid progenitor cells. Exp Hematol 23:362\u2013368","journal-title":"Exp Hematol"},{"key":"2106_CR203","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1177\/0748730402239679","volume":"18","author":"T Roenneberg","year":"2003","unstructured":"Roenneberg T, Wirz-Justice A, Merrow M (2003) Life between clocks: daily temporal patterns of human chronotypes. J Biol Rhythms 18:80\u201390. https:\/\/doi.org\/10.1177\/0748730402239679","journal-title":"J Biol Rhythms"},{"key":"2106_CR204","doi-asserted-by":"publisher","first-page":"11032","DOI":"10.1200\/jco.2008.26.15_suppl.11032","volume":"26","author":"S Iacobelli","year":"2008","unstructured":"Iacobelli S, Innominato P, Piantelli M, Bjarnason GA, Coudert B, Focan C, Giacchetti S, Poncet A, Garufi C, L\u00e9vi F (2008) Tumor clock protein PER2 as a determinant of survival in patients (pts) receiving oxaliplatin-5-FU-leucovorin as first-line chemotherapy for metastatic colorectal cancer (MCC). J Clin Oncol 26:11032\u201311032. https:\/\/doi.org\/10.1200\/jco.2008.26.15_suppl.11032","journal-title":"J Clin Oncol"},{"key":"2106_CR205","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.addr.2006.11.001","volume":"59","author":"F L\u00e9vi","year":"2007","unstructured":"L\u00e9vi F, Focan C, Karabou\u00e9 A, de la Valette V, Focan-Henrard D, Baron B, Kreutz F, Giacchetti S (2007) Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv Drug Deliv Rev 59:1015\u20131035. https:\/\/doi.org\/10.1016\/j.addr.2006.11.001","journal-title":"Adv Drug Deliv Rev"},{"issue":"8","key":"2106_CR206","first-page":"3038","volume":"6","author":"MC Mormont","year":"2000","unstructured":"Mormont MC, Waterhouse J, Bleuzen P, Giacchetti S, Jami A, Bogdan A, Lellouch J, Misset JL, Touitou Y, Levi F (2000) Marked 24h rest\/activity rhythms are associated with better quality of life better response and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res 6(8):3038\u20133045","journal-title":"Clin Cancer Res"},{"key":"2106_CR207","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.1098\/rsta.2008.0114","volume":"366","author":"F Levi","year":"2008","unstructured":"Levi F, Altinok A, Clairambault J, Goldbeter A (2008) Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Philos Trans A Math Phys Eng Sci 366:3575\u20133598. https:\/\/doi.org\/10.1098\/rsta.2008.0114","journal-title":"Philos Trans A Math Phys Eng Sci"},{"key":"2106_CR208","doi-asserted-by":"publisher","first-page":"961","DOI":"10.3332\/ecancer.2019.961","volume":"13","author":"C Pucci","year":"2019","unstructured":"Pucci C, Martinelli C, Ciofani G (2019) Innovative approaches for cancer treatment: current perspectives and new challenges. Ecancermedicalscience 13:961. https:\/\/doi.org\/10.3332\/ecancer.2019.961","journal-title":"Ecancermedicalscience"},{"key":"2106_CR209","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.2147\/ott.s53098","volume":"6","author":"D Chen","year":"2013","unstructured":"Chen D, Cheng J, Yang K, Ma Y, Yang F (2013) Retrospective analysis of chronomodulated chemotherapy versus conventional chemotherapy with paclitaxel carboplatin and 5-fluorouracil in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma. OncoTargets The 6:1507\u20131514. https:\/\/doi.org\/10.2147\/ott.s53098","journal-title":"OncoTargets The"},{"key":"2106_CR210","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00280-014-2558-x","volume":"74","author":"Z Akgun","year":"2014","unstructured":"Akgun Z, Saglam S, Yucel S, Gural Z, Balik E, Cipe G, Yildiz S, Kilickap S, Okyar A, Kaytan-Saglam E (2014) Neoadjuvant chronomodulated capecitabine with radiotherapy in rectal cancer: a phase II brunch regimen study. Cancer Chemother Pharmacol 74:751\u2013756. https:\/\/doi.org\/10.1007\/s00280-014-2558-x","journal-title":"Cancer Chemother Pharmacol"},{"key":"2106_CR211","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s00280-015-2804-x","volume":"76","author":"J Li","year":"2015","unstructured":"Li J, Chen R, Ji M, Zou SL, Zhu LN (2015) Cisplatin-based chronotherapy for advanced non-small cell lung cancer patients: a randomized controlled study and its pharmacokinetics analysis. Cancer Chemother Pharmacol 76:651\u2013655. https:\/\/doi.org\/10.1007\/s00280-015-2804-x","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-021-02106-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00109-021-02106-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-021-02106-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T12:35:21Z","timestamp":1672662921000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00109-021-02106-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,2]]},"references-count":211,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["2106"],"URL":"https:\/\/doi.org\/10.1007\/s00109-021-02106-x","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,2]]},"assertion":[{"value":"20 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}